IBEX 35
11.105,50 +55,40 (+0,50%) Euro Stoxx 50
5.085,08 +30,67 (+0,61%) Dólar/Euro
1,0772 -0,0012 (-0,11%) Petróleo Brent
82,73 -1,15 (-1,37%) Oro
2.366,90 +26,60 (+1,14%) Bitcoin EUR
56.696,93 +281,30 (+0,50%)
BioLineRx Ltd. (YP2A.F)
BioLineRx Ltd.
Modi’in Technology Park
2 HaMa’ayan Street
Hevel Modi'in 7177871
Israel
972 8 642 9100
https://www.biolinerx.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 79
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA | Chief Executive Officer | 554,37k | N/A | 1960 |
| Ms. Mali Zeevi CPA, CPA | Chief Financial Officer | 346,71k | N/A | 1976 |
| Dr. Ella Sorani Ph.D. | Chief Development Officer | 419,02k | N/A | 1968 |
| Ms. Holly W. May M.B.A. | President of BioLineRx USA | 658,2k | N/A | 1962 |
| Mr. John Lacey | Head of Corporate Communications & Investor Relations | N/A | N/A | N/A |
| Ms. Tsipi Keren-Lehrer B.Sc., L.L.B. | Head of BD & Strategic Advisor | N/A | N/A | N/A |
| Mr. Raziel Fried | Treasurer & Budgetary Control Director | N/A | N/A | N/A |
Descripción
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Gobierno corporativo
El ISS Governance QualityScore de BioLineRx Ltd., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
